氨磺必利与利培酮对照治疗首发精神分裂症患者疗效及安全性研究

A control study of amisulpride vs. risperidone in treatment of first-episode schizophrenia

目的探讨氨磺必利治疗首发精神分裂症患者的疗效及安全性。方法单药口服氨磺必利与单药口服利培酮对照治疗首发精神分裂症患者,于治疗前、治疗后4周、8周采用阳性和阴性综合征量表(PANSS)评定其病情严重程度及疗效,采用治疗中需处理的不良反应症状量表(TESS)评定其安全性。结果服用氨磺必利及利培酮治疗后,疗效显著,P均<0.05;两组间差异无显著性,P>0.05;服用氨磺必利后不良反应较少,与利培酮比较,差异有显著性,P<0.05。结论氨磺必利可有效改善首发精神分裂症患者症状,且安全性高。

Objective To explore the clinical efficacy and safety of amisulpride in treatment of first - episode schizophre- nia. Methods Single oral dose of tolbutamide will benefit and oral risperidone monotherapy in the treatment of first - episode schizophrenia patients, before and after treatment in 4 weeks and 8 weeks using the positive and negative syn- drome scale （PANSS） assessment of the severity of the disease and the curative effect, and adverse reactions with the treatment emergent symptom scale （TESS）. Results For taking amisulpride and risperidone treatment, obvious curative effect, P 〈 0. 05 ; The difference between the two groups was not significant, P 〉 0. 05 ; Taking adverse reactions after tolbutamide will benefit less, compared with risperidone, there was significant difference, P 〈 0. 05. Conclusion Tolbutamide can effectively improve symptoms in patients with schizophrenia, it has high safety.